- Home
- GYRE vs MUI Comparison
GYRE vs MUI Comparison
Compare GYRE & MUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- MUI
- Stock Information
- Founded
- GYRE 2002
- MUI 2003
- Country
- GYRE United States
- MUI United States
- Employees
- GYRE N/A
- MUI N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- MUI Investment Bankers/Brokers/Service
- Sector
- GYRE Health Care
- MUI Finance
- Exchange
- GYRE Nasdaq
- MUI Nasdaq
- Market Cap
- GYRE 1.1B
- MUI 915.7M
- IPO Year
- GYRE N/A
- MUI N/A
- Fundamental
- Price
- GYRE $10.95
- MUI $12.18
- Analyst Decision
- GYRE
- MUI
- Analyst Count
- GYRE 0
- MUI 0
- Target Price
- GYRE N/A
- MUI N/A
- AVG Volume (30 Days)
- GYRE 129.2K
- MUI 217.1K
- Earning Date
- GYRE 11-13-2024
- MUI 01-01-0001
- Dividend Yield
- GYRE N/A
- MUI 4.13%
- EPS Growth
- GYRE N/A
- MUI N/A
- EPS
- GYRE N/A
- MUI N/A
- Revenue
- GYRE $105,033,000.00
- MUI N/A
- Revenue This Year
- GYRE $25.32
- MUI N/A
- Revenue Next Year
- GYRE $12.95
- MUI N/A
- P/E Ratio
- GYRE N/A
- MUI N/A
- Revenue Growth
- GYRE N/A
- MUI N/A
- 52 Week Low
- GYRE $8.26
- MUI $9.73
- 52 Week High
- GYRE $26.37
- MUI $12.09
- Technical
- Relative Strength Index (RSI)
- GYRE 48.93
- MUI 43.77
- Support Level
- GYRE $9.51
- MUI $12.00
- Resistance Level
- GYRE $11.11
- MUI $12.28
- Average True Range (ATR)
- GYRE 0.85
- MUI 0.08
- MACD
- GYRE 0.04
- MUI 0.01
- Stochastic Oscillator
- GYRE 29.33
- MUI 64.29
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
About MUI BlackRock Municipal Income Fund Inc.
BlackRock Municipal Income Fund Inc is a diversified investment fund with an investment objective is to provide common shareholders with high current income exempt from U.S. federal income taxes. The company invests in Transportation, Corporate, County/City/Special District/School District, Health, Utilities, Education, Housing, and other sectors.